Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 12/2013

01.12.2013 | Bipolar Disorders (WH Coryell, Section Editor)

Toward Clinically Applicable Biomarkers in Bipolar Disorder: Focus on BDNF, Inflammatory Markers, and Endothelial Function

verfasst von: Benjamin I. Goldstein, L. Trevor Young

Erschienen in: Current Psychiatry Reports | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

The importance of biomarkers to many branches of medicine is illustrated by their utility in diagnosis and monitoring treatment response and outcome. There is much enthusiasm in the field of mood disorders on the emergence of clinically relevant biomarkers with several potential targets. While there are generally accepted criteria to establish a biomarker, such approaches are premature for our field as we acquire evidence on the most relevant candidates. A number of components of the inflammatory pathway are supported by published data together with an increasing focus on brain-derived neurotrophic factor. These markers may have measurable impacts on endothelial function, which may be particularly amenable to study in clinical samples. The adolescent population is a key focus as identifying biomarkers before the onset of comorbid medical conditions and which may help direct early intervention seem especially promising. A systematic approach to biomarker development in mood disorders is clearly warranted.
Literatur
1.
Hlatky MA et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408–16.PubMedCrossRef
2.
Pepe MS et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–61.PubMedCrossRef
3.
Kessler RC et al. National comorbidity survey replication adolescent supplement (NCS-A): III. Concordance of DSM-IV/CIDI diagnoses with clinical reassessments. J Am Acad Child Adolesc Psychiatry. 2009;48:386–99.PubMedCrossRef
4.
Merikangas KR et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49:980–9.PubMedCrossRef
5.
Osby U et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedCrossRef
6.
Goldstein BI et al. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009;11:657–62.PubMedCrossRef
7.
Fiedorowicz JG et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med. 2009;71:598–606.PubMedCrossRef
8.••
Frey BN et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatr. 2013;47:321–32. This article provides a comprehensive and broad-scoping review regarding peripheral biomarkers, as well as neurocognitive and neuroimaging intermediate phenotypes. It offers important insights regarding future potential directions for the field.CrossRef
9.••
Pfaffenseller B et al. Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother. 2013;13:827–42. This article comprises an up-to-date and detailed review of the leading classes of peripheral biomarkers in BD. It is clearly written and helpfully organized according to sub-topics.PubMedCrossRef
10.
Goldstein BI et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70:1078–90.PubMedCrossRef
11.
Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res. 2007;41:979–90.PubMedCrossRef
12.
Ridker PM et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.PubMedCrossRef
13.•
Rao JS et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15:384–92. An important high-impact article demonstrating the relevance of inflammation on a neuropathologic level in BD.PubMedCrossRef
14.
Maes M et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29:141–52.PubMedCrossRef
15.
Tsai SY et al. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 2001;64:185–93.PubMedCrossRef
16.
Ortiz-Dominguez A et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9:596–602.PubMedCrossRef
17.
Brietzke E et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116:214–7.PubMedCrossRef
18.
O'Brien SM et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90:263–7.PubMedCrossRef
19.
Dickerson F et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:952–5.PubMedCrossRef
20.
Tsai S-Y et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45:989–94.PubMedCrossRef
21.
Kim Y-K, Jung H-G, Myint A-M, Kim H, Park S-H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104:91–5.PubMedCrossRef
22.
Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 1999;33:335–40.PubMedCrossRef
23.
Knijff EM et al. An imbalance in the production of IL-1B and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9:743–53.PubMedCrossRef
24.
Liu H-C et al. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150:116–22.PubMedCrossRef
25.
Kim Y-K et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004;129:267–72.PubMedCrossRef
26.
Cunha AB et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258:300–4.PubMedCrossRef
27.••
Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144:16–27. One of three recent reviews on this topic, which together provide evidence of convergence in the literature, as well as a demonstration that inflammation-related findings in BD are holding up to the tests of time and independent replication.PubMedCrossRef
28.••
Munkholm K et al. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47:1119–33. One of three recent reviews on this topic, which together provide evidence of convergence in the literature, as well as a demonstration that inflammation-related findings in BD are holding up to the tests of time and independent replication.PubMedCrossRef
29.••
Modabbernia A et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74:15–25. One of three recent reviews on this topic, which together provide evidence of convergence in the literature, as well as a demonstration that inflammation-related findings in BD are holding up to the tests of time and independent replication.PubMedCrossRef
30.
Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116–27.PubMedCrossRef
31.
Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10:1089–93.PubMedCrossRef
32.
Lommatzsch M et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived neurotrophic functions. Am J Pathol. 1999;155:1183–93.PubMedCrossRef
33.
Gielen A et al. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol. 2003;57:493–7.PubMedCrossRef
34.
Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328:261–4.PubMedCrossRef
35.
Pan W et al. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37:1553–61.PubMedCrossRef
36.•
Klein AB et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347–53. This article provides further evidence that BDNF measured in blood is an adequate proxy for BDNF measured in brain tissue, which gives confidence that measuring BDNF in the blood of patients with BD may, indeed, reflect illness activity in the brain.PubMedCrossRef
37.
Lang UE et al. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry. 2007;62:530–5.PubMedCrossRef
38.
Geller B et al. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry. 2004;161:1698–700.PubMedCrossRef
39.
Tang J et al. Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China. Neurosci Lett. 2008;433:98–102.PubMedCrossRef
40.
Matsuo K et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology. 2009;34:1904–13.PubMedCrossRef
41.
Frey BN et al. Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder. Neuroreport. 2007;18:1567–70.PubMedCrossRef
42.
Lin P-Y. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett. 2009;466:139–43.PubMedCrossRef
43.
de Oliveira GS et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res. 2009;43:1171–4.PubMedCrossRef
44.••
Fernandes BS et al. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res. 2009;43:1200–4. Similar to recent meta-analyses regarding inflammation, this article provides evidence of convergence in the literature, as well as a demonstration that BDNF-related findings in BD are holding up to the tests of time and independent replication.PubMedCrossRef
45.
Machado-Vieira R et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry. 2007;61:142–4.PubMedCrossRef
46.
Cunha ABM et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398:215–9.PubMedCrossRef
47.
Fernandes BS et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995–1004.PubMedCrossRef
48.
Monteleone P et al. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 2008;10:95–100.PubMedCrossRef
49.
Kauer-Sant'Anna M et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12:447–58.PubMedCrossRef
50.
Dias VV et al. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 2009;11:663–71.PubMedCrossRef
51.
Tramontina JF et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett. 2009;452:111–3.PubMedCrossRef
52.
Kauer-Sant'Anna M et al. Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord. 2007;9 Suppl 1:128–35.PubMedCrossRef
53.
Palomino A et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res. 2006;86:321–2.PubMedCrossRef
54.
Grande I et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res. 2012;46:1511–4.PubMedCrossRef
55.
Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord. 1987;13:287–92.PubMedCrossRef
56.
Groner JA, Joshi M, Bauer JA. Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents. Pediatrics. 2006;118:1683–91.PubMedCrossRef
57.
Urbina EM et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension. 2009;54:919–50.PubMedCrossRef
58.
Cooper DC et al. Adverse impact of mood on flow-mediated dilation. Psychosom Med. 2010;72:122–7.PubMedCrossRef
59.
Lavoie KL et al. Association between clinical depression and endothelial function measured by forearm hyperemic reactivity. Psychosom Med. 2010;72:20–6.PubMedCrossRef
60.
Pizzi C et al. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J. 2008;29:1110–7.PubMedCrossRef
61.
Wagner JA et al. History of major depressive disorder and endothelial function in postmenopausal women. Psychosom Med. 2006;68:80–6.PubMedCrossRef
62.
Hemingway H et al. Social and psychosocial influences on inflammatory markers and vascular function in civil servants (the Whitehall II study). Am J Cardiol. 2003;92:984–7.PubMedCrossRef
63.
Rybakowski JK et al. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry. 2006;60:889–91.PubMedCrossRef
64.
Broadley AJM et al. Metyrapone improves endothelial dysfunction in patients with treated depression. J Am Coll Cardiol. 2006;48:170–5.PubMedCrossRef
65.
Rajagopalan S et al. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol. 2001;88:196–8.PubMedCrossRef
66.
Yang EH et al. Relation of depression to coronary endothelial function. Am J Cardiol. 2007;99:1134–6.PubMedCrossRef
67.
Fiedorowicz JG et al. Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study. Psychother Psychosom. 2012;81:235–43.PubMedCrossRef
68.
Ridker PM et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.PubMedCrossRef
69.
Buckley DI et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med. 2009;151:483–95.PubMedCrossRef
70.
Glowinska-Olszewska B, Tolwinska J, Urban M. Relationship between endothelial dysfunction, carotid artery intima media thickness and circulating markers of vascular inflammation in obese hypertensive children and adolescents. J Pediatr Endocrinol. 2007;20:1125–36.CrossRef
71.
Liu M et al. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther. 2009;23:369–76.PubMedCrossRef
72.
Dome P et al. Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol Psychiatry. 2009;14:523–31.PubMedCrossRef
73.
Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med. 2007;17:140–3.PubMedCrossRef
74.
Kermani P et al. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest. 2005;115:653–63.PubMed
75.
Ejiri J et al. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation. 2005;112:2114–20.PubMedCrossRef
76.
Manni L et al. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol. 2005;102:169–71.PubMedCrossRef
77.
Donovan MJ et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development. 2000;127:4531–40.PubMed
78.
Nakahashi T et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. 2000;470:113–7.PubMedCrossRef
79.
Li Q et al. Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J Neurosci Res. 2006;84:1656–68.PubMedCrossRef
80.
Zhang XY et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004;65:940–7.PubMedCrossRef
81.
Kobayashi K et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:658–63.PubMedCrossRef
82.
Padmos RC et al. A discriminating messenger RNA Signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65:395–407.PubMedCrossRef
83.
Pandey GN, et al. Proinflammatory cytokines in the plasma of patients with pediatric bipolar disorder. In: Massachusetts General Hospital Pediatric Bipolar Disorder Conference. Boston, MA.; 2009.
84.
Pandey GN et al. Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. J Am Acad Child Adolesc Psychiatry. 2008;47:1077–85.PubMedCrossRef
85.•
Goldstein BI et al. Preliminary findings regarding pro-inflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol. 2011;21:479–84. This is a small study that, nonetheless, extends findings from adults into BD among adolescence, and in so doing provides some biological support for the continuity and shared biology of adolescent and adult BD.PubMedCrossRef
86.
Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef
87.
Lovell DJ et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–9.PubMedCrossRef
88.
Goldstein BI et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008;69:1953–9.PubMedCrossRef
89.
Jerrell JM, McIntyre RS, Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry. 2010;71:161–8.CrossRef
90.
Evans-Lacko SE et al. Medical comorbidity among youth diagnosed with bipolar disorder in the United States. J Clin Psychiatry. 2009;70:1461–6.PubMedCrossRef
91.
Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687–700.PubMedCrossRef
92.
Correll CU. Elevated cardiovascular risk in patients with bipolar disorder: when does it start and where does it lead?[comment]. J Clin Psychiatry. 2008;69:1948–52.PubMedCrossRef
93.
Tomfohr LM et al. Multiwave associations between depressive symptoms and endothelial function in adolescent and young adult females. Psychosom Med. 2011;73:456–61.PubMedCrossRef
94.•
Dickerson F et al. A combined marker of inflammation in individuals with mania. PLoS One. 2013;8:e73520. Although this study examines different markers of inflammation than those described in most other articles on the topic, it takes the important step of combining multiple markers to enhance predictive capacity.PubMedCrossRef
95.
Kapczinski F et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1366–71.PubMedCrossRef
96.•
Monteggia LM. Toward neurotrophin-based therapeutics. Am J Psychiatry. 2011;168:114–6. This editorial puts forth the vantage that purposefully modifying neurotrophins may be a valuable approach in the coming years.PubMedCrossRef
97.
Nery FG et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23:87–94.PubMedCrossRef
98.
Muller N et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4.PubMedCrossRef
99.
Fletcher JM, Hughes RA. Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor. J Pept Sci. 2006;12:515–24.PubMedCrossRef
100.
Dickerson F et al. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150:456–9.PubMedCrossRef
101.
Barbosa IG et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord. 2012;137:151–5.PubMedCrossRef
Metadaten
Titel
Toward Clinically Applicable Biomarkers in Bipolar Disorder: Focus on BDNF, Inflammatory Markers, and Endothelial Function
verfasst von
Benjamin I. Goldstein
L. Trevor Young
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Psychiatry Reports / Ausgabe 12/2013
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-013-0425-9

Weitere Artikel der Ausgabe 12/2013

Current Psychiatry Reports 12/2013 Zur Ausgabe

Anxiety Disorders (DJ Stein, Section Editor)

Letter to the Editor: Recent Advances in Research on Cognition and Emotion in OCD: A Review

Personality Disorders (C Schmahl, Section Editor)

Antisocial Personality Disorder: A Current Review

Schizophrenia and Other Psychotic Disorders (SJ Siegel, Section Editor)

Use of Antipsychotic Medications in Pediatric Populations: What do the Data Say?

Eating Disorders (AS Kaplan, Section Editor)

Genetics of Eating Disorders

Anxiety Disorders (DJ Stein, Section Editor)

Translational Approaches to Anxiety: Focus on Genetics, Fear Extinction and Brain Imaging

Invited Commentary

Predicting Suicidal Behavior: Are We Really that Far Along? Comment on “Discovery and Validation of Blood Biomarkers for Suicidality”

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise